Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis
NCT04177940Phase 4Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of zoledronic acid, alendronate in glucocorticoid-induced osteoporosis (GIOP), sponsored by University of Alabama at Birmingham. Started Aug 2020; status: completed.
02
Drugs
zoledronic acidalendronate
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT04177940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177940.